0 277

Cited 0 times in

Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study

DC FieldValueLanguage
dc.contributor.author강은석-
dc.contributor.author김규리-
dc.contributor.author남정모-
dc.contributor.author이용호-
dc.contributor.author한유진-
dc.date.accessioned2017-11-02T08:06:26Z-
dc.date.available2017-11-02T08:06:26Z-
dc.date.issued2017-
dc.identifier.issn0020-7136-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154085-
dc.description.abstractRelationship on new statin use and the risk of hepatocellular carcinoma (HCC) in patients with incident type 2 diabetes mellitus (T2DM), who might be at the risk of developing HCC, is uncertained. A nationwide population-based nested case-control study was conducted within the National Health Insurance Service National Sample Cohort 2002-2013 in Korea. Newly prescribed statin after newly diagnosed T2DM was defined as statin use. Controls were matched to case patients on age, sex, follow-up time, and the date of diabetes diagnosis at a five-to-one ratio. Odds ratios (ORs) for associations of statin use with HCC were calculated using conditional logistic regression. After at least a 5-year HCC-free period, there were 229 incident HCC cases and 1,145 matched controls from 47,738 patients with incident diabetes. Of these 229 incident HCC cases, 27 (11.8%) were statin users, whereas 378 (33.0%) were statin users among 1,145 controls. Statin use was associated with a reduced risk of HCC development (adjusted OR [AOR]= 0.36, 95% confidence interval [CI] 0.22-0.60) after adjustment for chronic viral hepatitis, liver cirrhosis, alcoholic liver disease, previous cancer, aspirin use, insulin use, sulfonylurea use, metformin use, thiazolidinedione use, history of chronic obstructive pulmonary disease, Charlson comorbidity score, household income level, and residential area. Risk reduction was accentuated with an increase of cumulative defined daily doses (cDDD) compared with non-users (AORs 0.53, 0.36, 0.32, and 0.26 in ≤60, 60-180, 181-365, and >365cDDD, respectively; P for trend <0.0001). The risk reduction was apparent in the presence of liver disease (AOR = 0.27, 95% CI 0.14-0.50), including heterogeneous groups of clinical diagnosis of liver disease, but not significant in the absence of liver disease (AOR = 0.64, 95% CI 0.32-1.29). Among patients with new onset T2DM, statin use before HCC diagnosis may have a beneficial inhibitory effect on HCC development in a dose-dependent manner, especially in individuals with liver disease.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Liss-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHCarcinoma, Hepatocellular/epidemiology*-
dc.subject.MESHCase-Control Studies-
dc.subject.MESHComorbidity-
dc.subject.MESHDiabetes Mellitus, Type 2/drug therapy-
dc.subject.MESHDiabetes Mellitus, Type 2/epidemiology*-
dc.subject.MESHDyslipidemias/drug therapy-
dc.subject.MESHDyslipidemias/epidemiology-
dc.subject.MESHFatty Liver/epidemiology-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHepatitis, Viral, Human/epidemiology-
dc.subject.MESHHumans-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology*-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use-
dc.subject.MESHHypoglycemic Agents/therapeutic use-
dc.subject.MESHIncidence-
dc.subject.MESHLiver Neoplasms/epidemiology*-
dc.subject.MESHLogistic Models-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOdds Ratio-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHRisk-
dc.subject.MESHSocioeconomic Factors-
dc.titleEffect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorGyuri Kim-
dc.contributor.googleauthorSuk-Yong Jang-
dc.contributor.googleauthorEugene Han-
dc.contributor.googleauthorYong-ho Lee-
dc.contributor.googleauthorSe-young Park-
dc.contributor.googleauthorChung Mo Nam-
dc.contributor.googleauthorEun Seok Kang-
dc.identifier.doi10.1002/ijc.30506-
dc.contributor.localIdA00322-
dc.contributor.localIdA01264-
dc.contributor.localIdA02989-
dc.contributor.localIdA04311-
dc.contributor.localIdA00068-
dc.relation.journalcodeJ01092-
dc.identifier.eissn1097-0215-
dc.identifier.pmid27861855-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/ijc.30506/abstract-
dc.subject.keywordcohort study-
dc.subject.keyworddiabetes-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordliver disease-
dc.subject.keywordstatin-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.alternativeNameKim, Gyuri-
dc.contributor.alternativeNameNam, Jung Mo-
dc.contributor.alternativeNameLee, Yong Ho-
dc.contributor.alternativeNameHan, Eu Gene-
dc.contributor.affiliatedAuthorKim, Gyuri-
dc.contributor.affiliatedAuthorNam, Jung Mo-
dc.contributor.affiliatedAuthorLee, Yong Ho-
dc.contributor.affiliatedAuthorHan, Eu Gene-
dc.contributor.affiliatedAuthorKang, Eun Seok-
dc.citation.titleInternational Journal of Cancer-
dc.citation.volume140-
dc.citation.number4-
dc.citation.startPage798-
dc.citation.endPage806-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF CANCER, Vol.140(4) : 798-806, 2017-
dc.date.modified2017-11-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.